TabsDetailsBasic DetailsDate: Tuesday, June 7, 2016Type: PublicationMedical Product: antihyperglycemic drug, insulin, pioglitazone, saxagliptin, sitagliptin, sulfonylureaHealth Outcome(s): heart failureDescription: Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety of these antihyperglycemic agents. Objective: To examine the associations of hHF with saxagliptin and sitagliptin. Read More Materials: Ann Intern Med; Volume 164, Issue 11, Pages 705-714, DOI: 10.7326/M15-2568Additional InformationRelated Assessment(s): Anti-Diabetes Drugs and Acute Myocardial Infarction, Hospitalized Heart FailureA Protocol for Active Surveillance of Acute Myocardial Infarction in Association with the use of a New Antidiabetic Pharmaceutical AgentProspective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based StudySentinel Initiative Public Workshop - Ninth AnnualContributorsAuthor(s): Darren Toh ScD; Christian Hampp PhD; Marsha E. Reichman PhD; David J. Graham MD, MPH; Suchitra Balakrishnan; Frank Pucino; Jack Hamilton; Samuel Lendle; Aarthi Iyer MPH; Malcolm Rucker MS; Madelyn Pimentel BA; Neesha Nathwani; Marie R. Griffin MD, MPH; Nancy J. Brown; Bruce H. Fireman MA Corresponding Author: S. Toh, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215. Email: darren_toh@harvardpilgrim.org
